Active Ingredients: Norfloxacin
The Journal of Organic Chemistry ! It licensed use in acute and chronic complicated kidney infections has been withdrawn as a result.
McCann, and Orlando Acevedo.
The Journal of Physical Chemistry B . The Journal of Organic Chemistry .
The Journal of Organic Chemistry . Organic Letters . Azarmidokht Gholamipour-Shirazi and Christian Rolando. Konstantin Zhurov, Edmund J. Dickinson, and Richard G.
The Journal of Physical Chemistry B . Pengju Ji, John H.
Atherton, and Michael I. The Journal of Organic Chemistry . The Journal of Organic Chemistry .
Binghua Chai and Gerald H. The Journal of Physical Chemistry B .
Charles A. Lewis, Jr. Biochemistry .
The Journal of Physical Chemistry A . Reactivity Control by Anionic Components.
Fourteen patients 15 percent failed to show a response to treatment. Of the 48 patients with UTI and defined complications, 36 75 percent had a cure, three 6 percent showed improvement, and therapy failed in nine 19 percent.
Pregnancy Norfloxacin has been reported to rapidly cross the blood-placenta and blood-milk barrier, and is extensively distributed into the fetal tissues.
For this reason norfloxacin and other fluoroquinolones are contraindicated during pregnancy due to the risk of spontaneous abortions and birth defects.
The manufacturer only recommends use of norfloxacin during pregnancy when benefit outweighs risk. Ciprofloxacin is being licensed for the treatment of Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli and Inhalational Anthrax post-exposure and levofloxacin was recently licensed for the treatment of Inhalational Anthrax post-exposure.
However, the Fluoroquinolones are licensed to treat lower respiratory infections in children with cystic fibrosis in the UK.